NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球Divalproex Sodium市場:2021∼2028年

Global Divalproex Sodium Market - 2021-2028

出版商 DataM Intelligence 商品編碼 1023078
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
全球Divalproex Sodium市場:2021∼2028年 Global Divalproex Sodium Market - 2021-2028
出版日期: 2021年08月12日內容資訊: 英文 180 Pages
簡介

Divalproex Sodium,是FDA(美國食品藥物管理局)認證的抗癲癇藥,用於偏頭痛,躁鬱症的狂躁症發作,及某些類型的癲癇發作的治療。本劑以其用於治療癲癇的抗痙攣特性而聞名。

本報告提供全球Divalproex Sodium市場相關調查,市場概要,以及各劑型,各用途,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 全球Divalproex Sodium市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球Divalproex Sodium市場-市場定義和概要

第3章 全球Divalproex Sodium市場-摘要整理

  • 各劑型的市場明細
  • 各用途的市場明細
  • 各流通管道的市場明細
  • 各地區的市場明細

第4章 全球Divalproex Sodium市場-市場動態

  • 影響市場的要素
    • 駕駛者
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球Divalproex Sodium市場-產業分析

  • 波特的五力分析
  • PEST分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球Divalproex Sodium市場-COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19前的市場方案
    • COVID-19目前市場方案
    • COVID-19後或未來方案
  • Covid-19的價格動態
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球Divalproex Sodium市場-各用途

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場魅力指數
  • 癲癇和偏頭痛
    • 簡介
    • 市場規模分析,百萬美元,2018∼2028年,及與前一年同期比較成長分析(%),2020∼2028年
  • 躁鬱症
  • 其他

第8章 全球Divalproex Sodium市場-各劑型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各劑型
    • 市場魅力指數
  • 平板電腦
    • 簡介
    • 市場規模分析,百萬美元,2018∼2028年,及與前一年同期比較成長分析(%),2020∼2028年
  • 膠囊
  • 糖漿

第9章 全球Divalproex Sodium市場-各流通管道

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各流通管道
    • 市場魅力指數
  • 零售藥局
    • 簡介
    • 市場規模分析,百萬美元,2018∼2028年,及與前一年同期比較成長分析(%),2020∼2028年
  • 醫院藥局
  • 線上藥局

第10章 全球Divalproex Sodium市場-各地區

  • 簡介
    • 市場規模分析,百萬美元,2018∼2028年,及與前一年同期比較成長分析(%),2020∼2028年,各地區
    • 市場魅力指數
  • 北美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各劑型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場規模分析,及與前一年同期比較成長分析(%),各流通管道
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各劑型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場規模分析,及與前一年同期比較成長分析(%),各流通管道
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 南美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各劑型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場規模分析,及與前一年同期比較成長分析(%),各流通管道
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各劑型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場規模分析,及與前一年同期比較成長分析(%),各流通管道
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 中東和非洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各劑型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場規模分析,及與前一年同期比較成長分析(%),各流通管道

第11章 全球Divalproex Sodium市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業
  • 有顛覆性技術的企業
  • Start-Ups企業

第12章 全球Divalproex Sodium市場-企業簡介概要

  • Zydus Cadila Pharmaceuticals, Inc
    • 企業概要
    • 產品系列和概要
    • 主要的焦點
    • 財務概要
  • AbbVie Inc
  • Mylan N.V
  • Abbott Laboratories
  • Dr. Reddy's Laboratories Ltd
  • Lupin Limited
  • Orchid Chemicals & Pharmaceuticals Limited
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Abbott Laboratories

清單非網羅性

第13章 全球Divalproex Sodium市場-DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMPH3872

Divalproex Sodium Market Overview

The global divalproex sodium market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Divalproex sodium is an anti-epileptic drug approved by Food and Drug Administrator (FDA) used to treat migraine headaches, manic episodes of bipolar disorders, and certain types of seizures. It is known for its anticonvulsant properties for the treatment of epilepsy.

Divalproex Sodium Market Dynamics

The divalproex sodium market growth is driven by the growing prevalence of bipolar disorders, increasing patient pool with epilepsy and migraine headaches, and growing government initiatives and increasing research and development for the introduction of new products.

Increasing prevalence of bipolar disorders around the globe is expected to drive the growth in the forecast period

The increasing prevalence of bipolar disorders around the globe is propelling the divalproex sodium market growth. For instance, according to a study done by National Alliance on Mental Illness in 2017, the average age-of-onset of bipolar disorder is about 25, but it can occur in the teens, or more uncommonly, in childhood. The condition affects men and women equally, with about 2.8% of the U.S. population diagnosed with bipolar disorder and nearly 83% of cases classified as severe.

Increasing patient pool with epilepsy and migraine headaches is expected to drive the growth in the forecast period

The rising patient pool worldwide affected with epilepsy and migraine headaches is expected to boost demand for the divalproex sodium market significantly. For instance, according to the World Health Organization 2018 key facts, around 50 million people were globally affected with epilepsy, making it one of the most common neurological diseases, and around 80% of the people with epilepsy live in low- and middle-income countries.

According to the Migraine Trust Facts and Figures estimates, the global prevalence of migraine was 14.7% for the year 2013, that's around 1 in 7 people. Furthermore, increasing awareness regarding diseases and various government initiatives to prevent head migraines is expected to propel the divalproex sodium market size.

Increasing adverse effects of divalproex sodium is likely to hinder the market growth

The FDA gave a black boxed warning due to the hepatotoxicity, pancreatitis, and high fetal risk associated with the use of divalproex sodium tablets and other known adverse reactions such as congenital disabilities, neurobehavioral adverse effects, and suicidal behavior are expected to restrain the divalproex sodium market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has been continuing to transform the growth of various markets, the immediate impact of the outbreak is varied. While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Initially, the outbreak of COVID-19 showed an impact on the divalproex sodium market by directly affecting its production, creating supply chain disruptions, and creating a financial impact on firms due to social distancing and lockdown measures taken by the government. However, demand for divalproex sodium is expected to rise at a considerable pace in the coming years.

Divalproex Sodium Market Segment Analysis

The tablet segment is expected to hold largest share in this market segment

Divalproex sodium oral tablet is available in brand names Depakote ER and Depakote. Divalproex sodium is also used in various combinational therapies. The recommended initial dosage of Depakote for the treatment of bipolar disorders is 750 mg daily, whereas for complex partial seizures, the initial dosage starts with 10 to 15 mg/kg/day. Also, recommended starting dose for migraine headache is 250 mg twice daily to achieve a therapeutic response. Divalproex sodium extended-release tablets are valproate and are indicated for treating acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.

The epilepsy and migraine headaches segment are expected to hold largest share in this market segment

Epilepsy is one of the most common nervous system disorders which causes seizures. When there is an enduring predisposition to seizures, it is called epilepsy. It can affect people of any age, from children to adults of all races and backgrounds. For instance, seizures and epilepsy are some of the challenging health issues facing by many children. An epileptic seizure is said to be an abnormal electrical activity in your brain. It is a state of neurological activity that feels like a shock wave traveling through the brain, and the recurrence of these repetitive unprovoked seizures is called epilepsy.

Migraine is a medical condition that involves severe, recurring headaches and other symptoms. Before the headache, there may be sensory changes that are known as an aura. As per a 2018 article published by the American Academy of Family Physicians (AAFP), more than 15% of adults in the United States had experienced a migraine episode or a severe headache within three months. According to Migraine Research Foundation, 12% of the population, including children, suffers from migraines and around 18% of American women, 6% of men, and 10% of children experience migraines.

The rise in people getting affected by epilepsy and migraine headaches is projected to account for the largest market share during the forecast period. Epilepsy is triggered due to certain health conditions like brain tumors, strokes, brain infections, neurological defects, lack of oxygen to the brain, hyperpyrexia etc. Traumatic head and brain injuries, specific genetic conditions, smoking and drinking alcohol also led to epilepsy. At the same time, migraine is triggered due to hormonal changes, emotional triggers such as stress, depression, anxiety, Dietary factors like alcohol, caffeine, medications, and environmental factors.

In the present scenario, the living styles of people have induced anxiety and stress in their daily life due to which patient pool getting affected by epilepsy and migraine headaches is expected to increase during the forecast period and contribute as a driving factor divalproex sodium market.

The retail pharmacies segment is expected to hold largest share in this market segment

The retail Pharmacies segment is expected to dominate during the forecast period. Divalproex sodium drugs are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost market growth.

Divalproex Sodium Market Geographical Analysis

North America region holds the largest market share of global divalproex sodium market

In the North American region, the United States divalproex sodium market holds the major share. Rising government initiatives and increasing research and development for the introduction of novel products are expected to aid in the growth of the divalproex sodium market in the region. For instance, according to the Centers for Disease Control and Prevention, approximately 3 million adults and 470,000 children in the United States have epilepsy. According to a survey of 11 countries performed by Therapeutic Advances in Psychopharmacology, 2018, the lifetime prevalence of bipolar disorder was 2.4%, and out of that, 1% of prevalence was found in the United States, which is higher than other countries in the survey.

Divalproex Sodium Market Competitive Landscape

The global divalproex sodium market is moderately competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Zydus Cadila Pharmaceuticals, Inc., AbbVie Inc., Mylan N.V., Abbott Laboratories, Dr. Reddy's Laboratories Ltd., Lupin Limited, Orchid Chemicals & Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Abbott Laboratories. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in 2019 Lupin received the approval for divalproex sodium extended-release tablets USP 250 mg and 500 mg from the US FDA for commercializing generic equivalent of Depakote extended-release Tablets, 250 mg, and 500 mg, of AbbVie.

Divalproex Sodium Market Key Companies to Watch

Zydus Cadila Pharmaceuticals, Inc

Overview: Zydus Cadila, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. The origin of the company dates all the way back to the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.

Product Portfolio: The company portfolio includes New Chemical Entities, Biologics, Vaccines.

Key developments: In 2017, Zydus Cadila acquired Sentynl Therapeutics, a U.S.-based pharma company specialized in marketing of products in the pain management segment.

Why Purchase the Report?

  • Visualize the composition of the divalproex sodium market segmentation by application, by dosage form and by distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in divalproex sodium market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of divalproex sodium market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global divalproex sodium market report would provide an access to an approx. 61 market data table, 52 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation:

Global Divalproex Sodium Market- By Dosage Form

  • Tablet
  • Capsule
  • Syrup

Global Divalproex Sodium Market- By Application

  • Epilepsy and Migraine Headaches
  • Manic Depressive Illness
  • Others

Global Divalproex Sodium Market- By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Divalproex Sodium Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global Divalproex Sodium Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Divalproex Sodium Market - Market Definition and Overview

3. Global Divalproex Sodium Market - Executive Summary

  • 3.1. Market Snippet by Dosage form
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Distribution channel
  • 3.4. Market Snippet by Region

4. Global Divalproex Sodium Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Increasing prevalence of bipolar disorders around the globe
    • 4.1.2. Restraints:
      • 4.1.2.1. Increasing adverse effects of divalproex sodium
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Divalproex Sodium Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Divalproex Sodium Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Divalproex Sodium Market - By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Epilepsy and Migraine Headaches
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3 Manic Depressive Illness
  • 7.4 Others

8. Global Divalproex Sodium Market - By Dosage form

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage form
    • 8.1.2. Market Attractiveness Index, By Dosage form
  • 8.2. Tablet*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Capsule
  • 8.4. Syrup

9. Global Divalproex Sodium Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 9.1.2. Market Attractiveness Index, By Distribution channel
  • 9.2. Retail Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Hospital Pharmacies
  • 9.4. Online Pharmacies

10. Global Divalproex Sodium Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage form
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage form
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage form
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage form
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage form
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Divalproex Sodium Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start Up Companies

12. Global Divalproex Sodium Market - Company Profiles

  • 12.1. Zydus Cadila Pharmaceuticals, Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AbbVie Inc
  • 12.3. Mylan N.V
  • 12.4. Abbott Laboratories
  • 12.5. Dr. Reddy's Laboratories Ltd
  • 12.6. Lupin Limited
  • 12.7. Orchid Chemicals & Pharmaceuticals Limited
  • 12.8. Sun Pharmaceutical Industries Ltd
  • 12.9. Teva Pharmaceutical Industries Ltd
  • 12.10. Abbott Laboratories

LIST NOT EXHAUSTIVE

13. Global Divalproex Sodium Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us